Beam Therapeutics (BEAM) Preferred Stock Liabilities (2019)
Beam Therapeutics (BEAM) posted quarterly Preferred Stock Liabilities of $302.0 million for Q4 2019, up 1.1% quarter-over-quarter from $298.8 million in Q3 2019.
Powered by 
Analysis
Beam Therapeutics (BEAM) Preferred Stock Liabilities (2019) Analysis & Trends
Beam Therapeutics (BEAM) has reported Preferred Stock Liabilities for 1 consecutive years, with $302.0 million the latest figure, recorded in Q4 2019.
- In Q4 2019, Preferred Stock Liabilities changed N/A year-over-year to $302.0 million; the TTM figure through Dec 2019 stood at $302.0 million (changed N/A YoY), while the FY2019 annual figure was $302.0 million, changed N/A from the prior year.
- Preferred Stock Liabilities advanced to $302.0 million in Q4 2019 per BEAM's latest filing, from $298.8 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $302.0 million in Q4 2019 and bottomed at $292.3 million in Q1 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Beam Therapeutics | 3.10 Bn | 3.10 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2019 | 302.05 Mn |
| Sep 30, 2019 | 298.75 Mn |
| Jun 30, 2019 | 295.52 Mn |
| Mar 31, 2019 | 292.30 Mn |